The current reality and future prospects of less invasive technology for the treatment of BPH

1. Ponholzer A, Marszalek M, Madersbacher S. Minimally invasive treatment of BPH: an update. EAU Update Series 2004; 2: 24–33.

2. Tubaro A, Vicentini C, Renzetti R, Miano L. Invasive and minimally invasive treatment modalities for lower urinary tract symptoms: what are the relevant differences in randomised controlled trials. Eur Urol 2000; 38 (Suppl 1): 7–17.

3. Hoffman RM, Monga M, Elliot S et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev 2007; (4): CD004135.

4. Mattiasson A, Wagrell L, Schelin S et al. Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomised multicenter study. Urology 2007; 69(1): 91–6.

5. Xu WF, Zhang HB, Lin Z et al. Transrectal high-intensity focused ultrasound for treatment of benign prostatic hyperplasia: report of 262 cases. Nan Fang Yi Ke Da Xue Xue Bao. 2010; 30(8): 1906–1908.

6. Madersbacher S, Schatzl G, Djavan B, Stulnig T, Marberger M. Long-term outcome of transrectal highintensity focused ultrasound herapy for benign prostatic hyperplasia. Eur Urol 2000; 37: 687–694.

7. Chapple CR, Issa MM, Woo H. Transurethral needle ablation (TUNA). A critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia. Eur Urol 1999; 35: 119–128.

8. Bruskewitz R, Issa MM, Roehrborn CG et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998; 159: 1588–1594.

9. Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treat­ment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003; 44: 89–93.

10. Benoist N, Bigot P, Colombel P et al. Tuna: Clinical retrospective study addressing mid-term outcomes. Prog Urol 2009; 19(1): 54–9.

11. První zkušenosti s metodou TUNA (transurethral needle ablation) při léčbě BPH v ČR, P. Kumstát, D. Pacík, Urologická klinika FN Brno-Bohunice, Ces Urol 2002; 6 (1): 12–16.

12. Vanderbrink BA, Rastinehad AR, Badlani GH. Prostatic stents for the treatment of benign prostatic hyperplasia. Curr Opin Urol 2007; 17(1): 1–6.

13. Armitage JN, Cathcart PJ, Rashidian A et al. Epithelializing Stent for Benign Prostatic Hyperplasia: A Systematic Review of the Literature. J Urol 2007 May; 177(5): 1619–1624.

14. Westenberg A, Gilling P, Kennett K et al. Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomised trial with 4-year minimum long-term followup. J Urol 2004 Aug; 172(2): 616–619.

15. Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 2008 Jan; 53(1): 160–166.

16. Rieken M., Bachmann A. Vaporizace prostaty pomocí zeleného laseru (GreenLight laser) – zkušenost z jednoho centra po provedení více než 1 000 výkonů, Urol List 2012; 10(4): 22–26.

17. Al-Ansari A et al. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol. 2010 Sep; 58(3): 349–55.

18. Babjuk M, Dvořáček J, Janský M et al. Transuretrální intersticiální laserová koagulace a její využití v léčbě benigní hyperplazie prostaty. Endoskopie 2000; 9: 4–7.

19. Kursh ED, Concepcion R, Chan S et al. Interstitial laser coagulation versus transurethral prostate resection for treating benign prostatic obstruction: a randomized trial with 2-year follow-up. Urology 2003; 61: 573–578.

20. Herrmann T et al. Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction World J Urol 2010; 28: 45–51.

21. Goya N, Ishikawa N, Ito F et al. Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results. J Urol 2004; 172(3): 1017–20.

22. Nikoobakht M, Daneshpajooh A, Ahmadi H et al. Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: initial experience with Dysport. Scand J Urol Nephrol 2010; 44(3): 151–7.

23. Maria G, Brisinda G, Civello IM et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomised, placebo-controlled study. Urology 2003; 62(2): 259–64.

24. Kuo HC, Liu HT. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol 2009; 43(3): 206–11.

25. Dixon C, Rijo CE, Pacik D, Vit V, Varga V et al. Transurethral water vapor therapy for BPH; initial clinical results of the first in man trial and Rezūm™ I pilot study. European Urology Supplements, Volume 12, Issue 1 , Page e631, March 2013.

26. Miller F, Schönthaler M et al. The Prostatic Urethral Lift (PUL), a minimal-invasive transurethrally-placed implant, proves its efficacy in the treatment of LUTS in patients with BPH in daily clinic practice outside of studies, European Urology Supplements Volume 12, Issue 1, Pages ­­e629–­e630, March 2013.